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In 2014, the contraceptive implant was introduced into public sector 
facilities in South Africa (SA). Several thousand healthcare workers 
were trained, and demand was generated for the method, achieving 
high uptake. Use of the implant has since declined, but currently 
accounts for ~7% of all contraceptive use – a not insignificant 
achievement for a ‘new’ method.[1,2] In this edition of SAMJ, three 
articles[3-5] take stock of the early years of implant provision in SA. 
The articles, based on research in 2016, capture women’s motivations 
for using the implant and their perspectives towards the method; 
and healthcare providers’ competencies and experiences with service 
provision. Insights may be generalisable to family planning services 
more broadly, but are also relevant to the introduction of other new 
technologies, especially those related to HIV.
Counselling and choice 
As the implant was a ‘new’ method in the public health sector, one 
would have expected providers to give women detailed information 
about the benefits, potential side-effects and steps to follow should 
problems arise. This was not always the case, as pointed out by 
Pillay et al.[3] in this issue of SAMJ. For example, only about half of 
the clients interviewed in Johannesburg and the North West Province 
recalled being warned about side-effects, the principal cause of implant 
discontinuation. Moreover, only about a quarter remembered being 
informed about the method’s remarkable contraceptive effectiveness, 
the attribute that takes centre-place in family-planning counselling in 
many other countries.[6,7] Models, leaflets and flip charts can be used 
to facilitate such discussions.[8] In many settings, information about 
contraceptive methods is simply presented verbally – from most to least 
effective, beginning with the implant.[6,7] 
Among women who experience heavy or prolonged bleeding 
while using the implant, the decision to continue the method seems 
contingent on the dynamics of their relationship with their partner 
and the level of sexual activity. These issues need to be foregrounded in 
counselling for this group of women.[9,10] Encouragingly, Pillay et al.[3] 
found that many women had negotiated implant insertion, and indeed 
removal, with their partners. Others chose clandestine use, allowing 
them to use the implant without knowledge of their partners. Providers 
could raise this as an option, but then must inform women to consider 
the possibility of conflict with their partner, even violence, should the 
device be discovered. 
Clearly, providers’ confidence and competence to deliver a new 
contraceptive are critical to its success, as discussed by Adeagbo et al.[4] 
in a study of nurses in this edition of SAMJ. They found that providers 
generally felt inadequately prepared to carry out counselling, offer 
follow-up support and undertake removals. They ascribed these 
gaps mostly to deficiencies in training and, in particular, to the use 
of ‘cascade’ training methods. Even though the study did not directly 
examine providers’ willingness to offer the implant and changes in 
attitudes over time, reluctance to provide the contraceptive appears 
to be growing in the public sector, as negative experiences with the 
implant accrue. 
The promotion of specific methods over others is often justifiable, 
especially when a method holds compelling advantages for certain 
groups. In many settings, the implant is considered as ‘first-line’ for 
women within 48 hours of childbirth or after an abortion, as well as 
for adolescents and young women.[6,11-13] The study by Pillay et al.,[3] 
however, found no evidence that the youth were being targeted; only 
~15% of participants were aged 18 - 24 years, the age group with the 
highest unmet need for contraception.[1,14] Targeted implant provision 
is needed and creative approaches are called for. One possibility is to 
integrate implant provision into She Conquers,[15] a national campaign 
recently launched to address high rates of HIV, teen pregnancy, gender 
violence and school attrition among adolescent girls and young women 
in SA. Care must be taken to ensure that targeting does not occur 
simply on the basis of socioeconomic class, though. There is some 
evidence that such profiling is already occurring, with the income and 
educational levels of women who use the implant being considerably 
higher than those of the average woman in SA. This raises the question 
of whether providers are encouraging implant use among women of 
higher socioeconomic status, but favouring injectable contraceptives 
when counselling poorer clients.[14,16] 
Misconceptions and demand creation 
It is worth considering why instances of side-effects and implant 
removals spurred negative attention and press in SA, even though 
these seem similar to incidence rates elsewhere. Much of this may be 
related to the care and support provided to women who complain of 
side-effects, who are often told to persevere or wait for symptoms to 
settle, rather than being actively managed.[17] Both the women and 
nurses interviewed noted gaps in services for women who experienced 
side-effects. Providers need to be better equipped to precounsel women 
about anticipating side-effects, particularly bleeding changes. The 
highly variable treatment of problematic or intolerable bleeding by pro-
viders is a direct reflection of the lack of a standardised, evidence-based 
guideline on the medical management of these symptoms. In other 
settings, providers follow a clinical algorithm, laying out the counsel-
ling, treatment options and follow-up strategies for side-effects.[18,19] 
Bleeding in conjunction with other side-effects is particularly problem-
atic, and needs to be addressed proactively.[20,21] 
Women who tolerate a significant amount of discomfort and incon-
venience on the basis of advice from providers, may become justifiably 
angry about the care received and antagonistic towards the method 
itself. Other women who learn of these experiences understandably 
form negative impressions of the implant.[22] Equally, the voices of 
satisfied clients, who comprise the large majority of women who insert 
the implant, must be allowed to shape the public discourse about the 
method.[23] 
Even though few women cited pamphlets, television or social media 
as direct sources of information about the implant, these media could 
play an important role in reinforcing the testimonies of women who are 
satisfied with the method, and in counteracting negative perceptions 
and rumours before these become entrenched. Demand-creation 
efforts around the time of introducing the implant in SA, successfully 
generated positive impressions of the method. These efforts need to be 
redoubled, drawing on lessons from these early years. 
Programme monitoring
Having actionable data is especially important when a new 
contraceptive method is introduced. A method’s long-term success 
is often determined in these first years – indeed, delays in detecting 
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and rectifying problems in the past have resulted in many other 
methods being discarded.[24] An article by Pillay et al.,[5] published in 
this edition of SAMJ, examines the data-monitoring systems used in 
facilities, noting considerable gaps. A range of tools were being used 
to record insertions, while data were seldom captured on removals, 
and pharmacovigilance data not at all. Providers had developed their 
own registers, while the National Department of Health tools had 
been used in some facilities, but not in others, or different versions of 
the same tool were being used. Consequently, the actual numbers of 
insertions, incidence of complications, rates of removal and reasons 
for removal are largely unknown. Encouragingly, since the evaluation, 
many of these gaps in monitoring are being actively addressed. 
Conclusion 
Action is needed to ensure that the considerable gains made in the 
introductory phase of the implant translate into sustained uptake of the 
method in the long run. The potential of the implant to make a major 
contribution to reducing unintended pregnancies in SA is beginning to 
be realised, but gains could be substantially extended. 
Although commendable efforts were made to train healthcare 
workers with regard to implant use when it was first introduced in 
2014, refresher training is currently required. Key topics that have 
to be emphasised are counselling on the method’s effectiveness and 
side-effects, specific groups to target, management of side-effects and 
removal skills. Providers require clarity on implant use in women 
taking efavirenz. Even though levels of etonogestrel and therefore the 
contraceptive effectiveness of the implant are lowered in these women, 
they still have lower rates of pregnancy than women using other 
contraceptives, such as injectables.[25] Also, healthcare workers need 
to be reminded that the women they consult at clinics are those who 
have side-effects, and that the majority are highly satisfied with the 
method and do not return to the clinic. This predominance of visits for 
side-effects may well account for negative perceptions among providers 
towards the implant. 
It is worth investing in demand generation; the implant offers 3 years 
of highly effective protection against pregnancy, making it very cost 
effective. Targeting men is also important, given that many women 
consulted their partners prior to use and men held considerable 
influence over continuation. Data collected in one standardised tool, 
capturing a limited number of carefully selected variables, could guide 
improvements in the post-introductory phase. Robust monitoring data 
could trigger support for areas with low uptake, or training regarding 
management of side-effects in areas with high discontinuation rates. 
A sense of urgency is required to implement the recommended 
actions. The worst-case scenario – withdrawal of the implant from the 
method mix owing to dwindling uptake – is not as implausible as it 
might seem. Difficulties with new methods, when left unaddressed, 
often lead to their discontinuation.[24] Moreover, the possibility that 
depot medroxyprogesterone acetate will be withdrawn from the 
method mix owing to its association with HIV acquisition, provides 
a particularly compelling reason for shoring up the performance of 
implant provision.[15] Importantly, the findings in this series pose 
searching questions about the performance of the family-planning 
programme in general. It is time to consider the inclusion of 
contraception in the package of services available in the postpartum 
ward, HIV clinics and several other clinical settings. The traditional 
approach of restricting the provision of contraception to family-
planning clinics may well be responsible for the slow progress made in 
reducing unintended pregnancies in the country.
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